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DOI 10.1016/j.cell.2010.02.029Nonresolving inflammation is a major driver of disease. Perpetuation of inflammation is an inherent
risk because inflammation can damage tissue and necrosis can provoke inflammation. Nonethe-
less, multiple mechanisms normally ensure resolution. Cells like macrophages switch phenotypes,
secreted molecules like reactive oxygen intermediates switch impact from pro- to anti-inflamma-
tory, and additional mediators of resolution arise, including proteins, lipids, and gasses. Aside
from persistence of initiating stimuli, nonresolution may result from deficiencies in these mecha-
nisms when an inflammatory response begins either excessively or subnormally. This greatly
complicates the development of anti-inflammatory therapies. The problem calls for conceptual,
organizational, and statistical innovations.Inflammation is a frequent occurrence because we are partly
microbial and we move in a microbial world. These circum-
stances ensure countless encounters with microbial stimuli in
the context of tissue injury. The conjunction of these two types
of stimuli in time and space is what most often initiates inflamma-
tion (Nathan, 2002). The usual result of inflammation is protection
from the spread of infection, followed by resolution—the restora-
tion of affected tissues to their normal structural and functional
state.
The problem with inflammation is not how often it starts, but
how often it fails to subside. Perhaps no single phenomenon
contributes more to the medical burden in industrialized socie-
ties than nonresolving inflammation. Nonresolving inflammation
is not a primary cause of atherosclerosis, obesity, cancer,
chronic obstructive pulmonary disease, asthma, inflammatory
bowel disease, neurodegenerative disease, multiple sclerosis,
or rheumatoid arthritis, but it contributes significantly to their
pathogenesis.
This illustrative but noncomprehensive review begins by
describing different forms of nonresolving inflammation. We
then discuss damage of uninfected tissues as a propagator of
inflammation. This is a critical conceptual issue, because micro-
bial stimuli are not implicated inmany forms of chronic inflamma-
tion, and it is instructive to appreciate the adaptive value of our
ability to launch a tissue-damaging process triggered by tissue
damage itself. Next, we ask two questions interchangeably
that mirror each other: How does inflammation resolve? How
can resolution fail? Given that the answers are complex and
incomplete, we close by considering implications for the future
of anti-inflammatory therapy.
Examples of Nonresolving Inflammation
Nonresolving inflammation can take distinct histologic forms, as
illustrated in Figure 1. These can succeed each other or coexist
in different sites in an affected organ.Inflammation sometimes progresses from acute to chronic
and then stalls for a prolonged period, although signs of acute
inflammation, such as accumulation of neutrophils, may reap-
pear later. Classic examples involve persistent infections. The
contribution of inflammation to pathogenesis deserves em-
phasis when the host inflammatory response, not toxins from
the pathogen, is chiefly responsible for the damage to the
host. Globally, tuberculosis is probably the most prevalent
example. Chronic inflammation surrounding Mycobacterium
tuberculosis can persist for decades. When the inflammation is
extensive enough, it liquefies lung. The host suffers loss of respi-
ratory capacity and sometimes blood; the pathogen gets a ride
on infectious droplets to enter another host.
An enormous proportion of the global burden of disease
involves nonresolving inflammation that appears to be chronic
from the outset, in that the first cellular signs of inflammation
involve infiltration of the tissue by monocytes, dendritic cells,
and macrophages. Examples include atherosclerosis (Galkina
and Ley, 2009), obesity (Nathan, 2008), and some cancers (Man-
tovani et al., 2008).
Frequently, acute and chronic inflammation coexist over long
periods, implying continual reinitiation. Examples are found in
rheumatoid arthritis, asthma, chronic obstructive pulmonary
disease, multiple sclerosis, Crohn’s disease, ulcerative colitis,
and cancers whose stroma is infiltrated both by macrophages
and immature myeloid cells (Mantovani et al., 2008). For
example, in rheumatoid arthritis, the synoviumpresents a striking
picture of chronic inflammation, with extensive infiltration by
macrophages and lymphocytes and activation of synoviocytes.
In contrast, the synovial fluid is a sea of neutrophils. The effusion
in an affected joint of an untreated patient with rheumatoid
arthritis can be invaded by over a billion neutrophils per day
that have a half-life of about 4 hr (Hollingsworth et al., 1967).
Neutrophils contain cytosolic peptidyl arginine deiminase type 4,
an enzyme whose activity depends on the levels of Ca2+ foundCell 140, 871–882, March 19, 2010 ª2010 Elsevier Inc. 871
Figure 1. Examples of Nonresolving Inflammation
(A) Atherosclerosis. Plaque from a human carotid artery containing macro-
phages stained with anti-CD68.
(B) Obesity. Abdominal adipose tissue from an obese mouse with necrotic
adipocytes (asterisks) surrounded by macrophages. Nuclei of some T cells
are stained with anti-Foxp3.
(C) Rheumatoid arthritis. Synovium from a human knee infiltrated by lympho-
cytes, monocytes, and activated fibroblasts. Cells in the joint space (top),
mostly neutrophils, are lost in sample preparation.
(D) Pulmonary fibrosis after conditional overexpression of TGF-b. Collagen is
stained blue; smooth muscle cells are stained brown.
Images are used with permission from the following: Sato, K., Niessner, A.,
Kopecky, S.L., Frye, R.L., Goronzy, J.J., and Weyand, C.M. (2006). TRAIL-
expressing T cells induce apoptosis of vascular smooth muscle cells in the
atherosclerotic plaque. J. Exp. Med. 203, 239–250 (A). Feuerer M., Herrero,
L., Cipolletta, D., Naaz, A., Wong, J., Nayer, A., Lee, J., Goldfine, A.B., Benoist,
C., Shoelson, S., and Mathis, D. (2009). Lean, but not obese, fat is enriched for
a unique population of regulatory T cells that affect metabolic parameters. Nat.
Med. 15, 930–939 (B). Reprinted by permission from Macmillan Publishers
Ltd: Firestein, G. (2003). Evolving concepts of rheumatoid arthritis. Nature
423: 356–361, copyright 2003 (C). Lee, C.G., Cho, S.J., Kang, M.J., Chapoval,
S.P., Lee, P.J., Noble, P.W., Yehualaeshet, T., Lu, B., Flavell, R.A., Milbrandt,
J., Homer, R.J., and Elias, J.A. (2004). Early growth response gene 1–mediated
apoptosis is essential for transforming growth factor 1–induced pulmonary
fibrosis. J. Exp. Med. 200, 377–389 (D).in extracellular fluid. When neutrophils die, this enzyme may be
released and activated. It may then convert the guanidino side
chains of L-arginine residues to ureido residues, generating
citrulline in some proteins in the joint. The autoantibodies most
closely associated with the pathogenesis of rheumatoid arthritis
react with citrullinated proteins (Uysal et al., 2009). Thus, dying
neutrophils may help sustain an ongoing antigen-antibody
reaction that attracts and activates more neutrophils, whose
secretion of oxidants and proteases is synergistically destructive
(Han et al., 2005).
Successful postinflammatory tissue repair requires the coordi-
nated restitution of different cell types and structures, not only872 Cell 140, 871–882, March 19, 2010 ª2010 Elsevier Inc.epithelial and mesenchymal cells but also extracellular matrix
and vasculature. Chemokines are critical to vascular remodeling
after inflammation (Strieter et al., 2007). Without appropriate
restitution of vasculature, altered tissue oxygenation may pre-
clude normal repair, resulting in atrophy or fibrosis. When these
processes destroy an organ, we do not know how to restore
normal function short of replacing the organ by transplantation.
Atrophy refers to the loss of parenchymal cells. For example,
atrophy of the stomach follows longstanding inflammation
caused by infection with Helicobacter pylori, resulting in loss of
mucosal function and failure to produce gastric acid. Atrophy
is often accompanied by expansion of extracellular tissue
elements, particularly collagen, resulting in fibrosis, the deposi-
tion of excess connective tissue. It is likely that atrophy some-
times promotes fibrosis, fibrosis sometimes promotes atrophy,
and each can occur independently. Both can arise without
known preceding inflammation.
Fibrosis sufficient to interfere with organ function is a major
medical problem after inflammation of arteries caused by accu-
mulation of cholesterol, inflammation of the liver caused by
viruses, alcohol, toxins or schistosome infections, inflammation
of the lung associated with asthma or radiotherapy, and inflam-
mation of the bowel in Crohn’s disease, where fibrotic strictures
(occlusions) often require surgery. Fibrosis arises from the
excessive number, activity, or life span of collagen producing
cells—activated fibroblasts, epithelial cells that undergo trans-
formation to a mesenchymal phenotype, hepatic stellate cells
that generate myofibroblasts, and bone marrow-derived fibro-
cytes that enter an affected organ from the circulation. Various
chemokines attract fibrocytes into an inflammatory site, where
TGF-b promotes their differentiation (Abe et al., 2001; Strieter
et al., 2007). Also important are the factors governing the
apoptosis of collagen-producing cells during the resolution of
inflammation.
TLR agonists can activate fibroblasts directly (Wynn, 2008).
Cytokines with a prominent role in promoting fibrosis include
TGF-b, IL-13, IL-4, IL-6, and IL-21. Directly or through their
influence on chemokine expression, these cytokines can recruit
and augment the proliferation of fibrocytes, fibroblasts, and
myofibroblasts and promote their production of collagen (Wilson
and Wynn, 2009; Wynn, 2008). IL-4 induces macrophages to
express TGF-b, PDGF, and arginase. Ornithine, a product of
arginase, is a significant source of the proline and hydroxyproline
that together account for almost a quarter of the residues in
collagen. TGF-b activity is post-translationally regulated by
release from latency-associated protein, often by proteolysis.
For this and additional reasons, the balance between proteases
and antiproteases (which in turn is critically regulated by reactive
oxygen intermediates, or ROI) may play a large role in the degree
of fibrosis that follows inflammation. TGF-b induces mesen-
chymal cells to express NADPH oxidase 4 (NOX4), whose
production of ROI mediates TGF-b-dependent myofibroblast
differentiation and extracellular matrix production (Hecker
et al., 2009). IL-13 promotes both the production of TGF-b by
macrophages and its proteolytic activation, although IL-13 can
also promote fibrosis independently of the TGF-b/Smad
signaling pathway (Wynn, 2008). Macrophage- and fibroblast-
derived angiotensin II is another profibrotic stimulus that works
Figure 2. Initiation of Prolonged Inflammation Usually Requires
Signals from Both Microbes and Injured Tissue
Transient, functionally consequential inflammation can also arise when large
numbers of host cells undergo necrotic death without involvement of microbial
products, most often from ischemic events. Their products activate many of
the receptors that detect microbes.at least in part through augmentation of TGF-b production
(Wynn, 2008). Bioactivity of TGF-b is further controlled by the
expression of matrix proteins that bind it in an inactive state.
Endogenous antagonists of fibrosis include IFN-g, IL-12, IL-10,
and IL-13aR2, a decoy receptor (Wynn, 2008). Shared actions
of IFN-g and IL-10 are uncommon, and it will be fruitful to learn
more about how each of them suppresses fibrosis.
In sum, tissue healing has features in common with tissue
development, which requires involution of pre-existing tissue
elements. However, distinct challenges arise when the pre-
existing tissue has been damaged and inflamed. It is not just
the expression or extinction of certain mediators that is critical,
but the orchestration of their succession—that is, their tuning
and timing.
Tissue Damage as an Initiator or Propagator
As hinted above, inflammation can reduce any site in the body to
a liquid that contains few living cells or intact macromolecules, or
harden it into a mass packed with infiltrating lymphohemato-
poietic cells or stiffened by collagen. What if tissue damage, in
turn, were to trigger inflammation?Wouldn’t that set up a positive
feedback loop that could send us all to an early grave?
By itself, sterile tissue injury, as generated by well-performed
surgery, provokes little or no clinically apparent inflammation.
Fortunately, since we are human-microbial consortia, the pres-
ence of microbial products in the absence of tissue injury is
noninflammatory as well. As mentioned, it is when signals arising
from tissue injury coincide with signals arising from microbes
that inflammation usually ensues (Nathan, 2002). Nonetheless,
inflammation does arise when large numbers of host cells die
in place, such as in a heart attack or stroke. Although inflamma-tion in such settings usually resolves quickly, it often contributes
to the damage precipitated by the underlying event.
Why have we evolved to allow noninfectious cell death to
trigger a response that exacerbates noninfectious cell death?
An evolutionary perspective suggests an explanation, as sum-
marized in Figure 2. The host senses microbial products in two
ways: directly, via host molecules that bind microbial products,
and indirectly, by host molecules that detect products of host
cell necrosis. Microbial products can reach host detectors in
two ways: by direct contamination of tissues, such as via cuts,
bites or burns, or by diffusion of secreted, shed, or released
microbial products through extracellular fluid, lymph, or blood.
The host needs to be particularly vigilant in detecting microbial
toxins that diffuse or circulate because toxins can allow a tiny
bacterial biomass to incapacitate a vastly larger host. Relying
on a receptor to detect a toxin may provide less warning than
relying on multiple receptors to detect the damage the toxin
causes. Making an advantage of necessity, the host uses
necrosis of its cells as one of the immune system’s earliest and
best-amplified signals to report the dissemination of a microbial
toxin. In evolution, sterile surgical technique was unknown,
ischemic events like heart attacks and strokes—largely afflic-
tions of the elderly—would not have imposed large selective
pressures, and most cases of tissue injury that exerted large
selective pressures in individuals with reproductive potential
were contaminated by or caused by microbes. Thus, it is plau-
sible that animals have evolved to interpret necrotic host cells
as a sign of infection.
The molecular signals of host cell necrosis that trigger inflam-
mation are still being defined and debated (Kono and Rock,
2008), but they are many and diverse. Examples include uric
acid, adenosine, oxidized 1-palmitoyl-2-arachidonyl-phosphati-
dylcholine (Imai et al., 2008), chromosomal DNA (Okabe et al.,
2009), IL-1a, IL-33, high-mobility group box-1 (HMGB1), non-
muscle myosin recognized by complement-fixing antibodies
present in normal mice (Zhang et al., 2006), and fragments of
extracellular matrix proteins generated by release of proteases
from dying cells (Kono and Rock, 2008). Reflecting the extremely
close relationship between detection of microbial products and
detection of host cell injury, many, perhaps most, of the host
molecules that specifically recognize microbial products also
recognize one or another host product whose formation or reloc-
alization reports host cell necrosis.
This sets the stage to consider mechanisms that drive the
resolution of inflammation and how they may sometimes fail,
as summarized in Figure 3.
Mechanisms of Resolution and Nonresolution
We avoid spontaneous inflammation through a set of tonically
operating anti-inflammatory mechanisms. This was inferred
from the phenotype resulting from loss-of-function mutations
in what were earlier counted as over 50 genes (Nathan, 2002),
and are now recognized as at least 81 (Table 1; for abbreviations
and references, see Table S1 available online). These mutations
lead to spontaneous emergence of persistent inflammation in
people living in normal conditions or in laboratory mice during
standard husbandry—that is, without a known inflammatory
provocation, and without evident autoimmunity. Apparently, itCell 140, 871–882, March 19, 2010 ª2010 Elsevier Inc. 873
Figure 3. Mechanisms and Consequences
of Nonresolution of Inflammationtakes a complex, coordinated response by 81 or more gene
products to prevent inflammation from arising spontaneously.
The true number is likely to be higher, given what this list implies:
that spontaneous inflammation may arise whenever we lose a
nonredundant component of a mechanism that regulates prolif-
eration or signaling in lymphoid, myeloid, or epithelial cells
responding to antigens, microbes, or injury.
Examples involving those three cell types are instructive.
TNF-a-induced protein-2 (TIPE2) is selectively expressed in
lymphoid cells and acts to dampen signals from the T cell
receptor and TLRs (Sun et al., 2008). Mice that lacked TIPE2
died from accumulation of lymphocytes and macrophages in
their lungs, liver, and intestines and of inflammatory cytokines
in their blood (Sun et al., 2008). Similarly, loss of function of a
myeloid-specific microRNA led to overproliferation and hyperac-
tivity of granulocytes and to spontaneous development of inter-
stitial pneumonitis (Johnnidis et al., 2008). When oxidation or
mistranslation of proteins leads to their unfolding, the endo-
plasmic reticulum membrane-spanning enzyme IRE1 activates
a transcription factor, X box binding protein 1. Mice in which
XBP1 was selectively deleted from intestinal epithelial cellsTable 1. Gene Products Required to Maintain Basal Anti-inflammatory Tone
Functional Class Gene Product
Regulation of Apoptosis and Clearance of Apoptotic Cells Fas, Fas, C1q, C1q, C2, C4, C4, C3,
DNAse II, FcgRIIB, WASP, WASP, c-
Cytokines and Cell Surface Receptors TNFR1, TNFR1, TGF-b1, IL-2Ra, IL-2
IL-1Ra, TcRa, TcR b, MHCII, CTLA4,
Other Membrane or Intracellular Proteins of Lymphocytes,
Leukocytes, or Epithelial Cells Affecting Their Activation
ZAP70,MDR1a, LAT, TSAd, SOCS1,
SHIP, p21, TIA-1, tristetraproline, A2
Rel-b, NF-kB1, Ndfip1, T-bet, Gadd4
pyrin, cryopyrin, mevalonate kinase,
JunB/cJun, TRAF6, CAT2, PSTPIP1,
SH3BP2, TAK1, XBP1
Other Heme oxygenase 1, surfactant prote
Proteins encoded by genes whose mutation leads to spontaneous inflammatory states not attributable
are underlined; others are mouse. For abbreviations and references, see Table S1. This table is updat
874 Cell 140, 871–882, March 19, 2010 ª2010 Elsevier Inc.developed neutrophilic accumulations
in their small intestines, along with ab-
scesses and ulcers (Kaser et al., 2008).
In humans, hypomorphic variants of
XBP1 are associated with Crohn’s dis-
ease (Kaser et al., 2008).
It is likely that mechanisms of similar
diversity and complexity operate to
resolve inflammation once it has arisen.
Below, we illustrate some of the cellular
and soluble factors involved. Space is
lacking to discuss the many intracellular
signaling molecules that impose checks
and balances on proinflammatory path-ways, such as protein and lipid phosphatases, kinase-inhibiting
proteins, ubiquitin ligases, and transcriptional regulators.
Cells Contributing to Resolution
Perhaps the most important reason that host cell death without
microbial involvement rarely triggers nonresolving inflammation
is that the death is usually apoptotic; apoptotic cells are ingested
by viable cells, typically macrophages; and ingestion of apo-
ptotic cells triggers macrophages to release inflammation-
resolving cytokines such as TGF-b and IL-10 (Huynh et al.,
2002; Kennedy and DeLeo, 2009). Glucocorticoids, whose levels
are often increased in response to the stress associated with an
inflammatory condition, promote ingestion of apoptotic cells by
macrophages and their release of TGF-b and IL-10 (Kennedy and
DeLeo, 2009).
In contrast, if apoptotic cells are not ingested rapidly, they
often progress to necrosis. Necrosis releases products that are
agonists, or generate agonists, for host receptors that also
detect microbial products and that generate proinflammatory
signals. Inflammation can thus be prolonged by a failure of
neutrophils to undergo timely apoptosis or by a failure of macro-
phages to clear those that apoptose. Neutrophil survival isC4 BP, factor H, Crry, SAP, DNAse I,
mer, caspase 8, TIPE2
, IL-10, IL-10R, GM-CSF, GM-CSF, IL-1Ra,
PD1, TAC1, aEb7 (CD103), av integrin
PI3K p110d, PTEN, lyn, cbl-b, Gai2, SHP-1,
0, NFAT, IKK-2, IKKg, IKKg, IkBa, IkBa,
5a, IRF-2, RabGEF1, NOD2/CARD15,
Foxj1, Foxo3a, p120-catenin, RXRa/b,
PSTPIP2, a-mannosidase-II, RUNX3,
in D, STAMP2, miR-223
to infection or autoimmunity. Human products
ed from Nathan (2002).
prolonged in many inflammatory states by the ability of GM-CSF
and G-CSF to induce the apoptosis inhibitor survivin (Altznauer
et al., 2004) and the ability of hypoxia inducible factor-1a to
induce glycolytic enzymes (Cramer et al., 2003) that support
ATP generation under hypoxic conditions. Although comple-
ment activation is generally proinflammatory, dependence of
apoptotic cell clearance on complement implies that inflamma-
tionmight be prolonged in the face of a deficiency in the comple-
ment system (Mevorach et al., 1998). Likewise, inflammation
might be prolonged by deficiency of other factors that promote
ingestion of apoptotic cells, such as the secreted glycoprotein
milk fat globule-EGF-factor 8 (MFG-E8) (Hanayama et al.,
2002), or TIM4, a macrophage receptor for the phosphatidylser-
ine exteriorized by apoptotic cells (Miyanishi et al., 2007).
Along with the contrasting impact of encountering apoptotic
or necrotic cells, there are other ways in which macrophages
normally switch from being proinflammatory at the outset of an
inflammatory response to anti-inflammatory later in the process.
For example, in wound healing, inflammatory monocytes
accumulate in damaged tissue and are essential for its repair
(Arnold et al., 2007). In unexplained contrast to the impact of
products of necrotic cells, phagocytosis of tissue debris can
induce mononuclear phagocytes to switch from a proinflamma-
tory to an anti-inflammatory phenotype that promotes muscle
cell differentiation in conjunction with production of elevated
amounts of TGF-b (Arnold et al., 2007). TGF-b is a potent sup-
pressor of what is now called classical macrophage activation
(Tsunawaki et al., 1988) and a critical mediator of tissue repair.
Tissue damage also promotes production of glucocorticoid
hormones. These, too, can convert monocytes/macrophages
from a proinflammatory to anti-inflammatory state (Ehrchen
et al., 2007; Perretti and D’Acquisto, 2009). IL-4 released by
mast cells, basophils, and Th2 cells provides another cue for
macrophages to switch from a classically activated, proinflam-
matory phenotype to one that suppresses inflammation and
favors wound healing, including through production of IL-10
(Mosser and Zhang, 2008). After TGF-b, IL-10 was the second
cytokine produced by nontransformed cells that was discovered
to be a potent suppressor of classical macrophage activation
(Bogdan et al., 1991).
In some settings, a profile of cell surface markers and molec-
ular products distinguishes macrophage populations that carry
out two distinct aspects of resolution—suppression of inflamma-
tion and promotion of tissue repair (Mosser and Edwards, 2008).
It is not clear whether this reflects alternative pathways of differ-
entiation on the part of cells in the affected tissue or sequential
recruitment of cells with different profiles. In the myocardium of
mice after occlusion of a coronary artery, shifts over time in
expression of chemokines and adhesion molecules allowed
sequential recruitment of different monocyte populations. The
first monocyte population contributed to the evolving inflamma-
tory response and the second to its resolution (Nahrendorf et al.,
2007). The monocytes that predominated in the damaged tissue
from days 1–4 were Ly6Chigh cells mobilized largely from the
spleen in response to angiotensin II (Swirski et al., 2009). These
cells entered the heart in response to signaling via CCR2,
expressed high levels of matrix metalloproteinases and TNF-a,
and were required for degradation of the damaged tissue(Nahrendorf et al., 2007). From days 5 through 16, themost prev-
alent monocytes were Ly6Clo cells responding via CX3CR1; they
expressed far less matrix metalloproteinases but high levels of
VEGF and contributed to angiogenesis and deposition of
collagen (Nahrendorf et al., 2007).
Distinct from the macrophage populations discussed above
are myeloid-derived suppressor cells, a heterogeneous group
of myeloid progenitors that expand rather than differentiate
in response to prostaglandins, VEGF, and other factors that
activate STAT3. They can accumulate in the spleen and blood
and enter cancers, infected sites, and inflamed organs in mice
with inflammatory bowel disease, experimental allergic enceph-
alomyelitis, or experimental autoimmune uveitis (Gabrilovich and
Nagaraj, 2009). Through inducible nitric oxide synthase (iNOS)-
dependent production of peroxynitrite and arginase-mediated
consumption of L-arginine, among other means, these cells
can profoundly suppress T cell responses (Gabrilovich and
Nagaraj, 2009). Given that effector T cell-derived chemokines
and macrophage-activating factors can contribute to progres-
sion of inflammation, suppression of T cells may help inflamma-
tion resolve. On the other hand, premature abrogation of T cell
effector functions may allow inflammatory stimuli to persist.
For example, suppressed T cells may fail to restrain the growth
of chemokine-secreting cancer cells that prolong inflammation,
further inducing the expansion and activation of myeloid-derived
suppressor cells.
There are diverse additional ways in which an abnormal T cell
response could lead to prolonged inflammation. T regulatory
cells (see Review by D.R. Littman and A.Y. Rudensky on page
845 of this issue) can suppress inflammation (Garrett et al.,
2007). A deficiency in T regulatory cells appears to contribute
to the persistent inflammation of visceral adipose tissue in
obesity (Lo, 2009). The T cell products IFN-g and TNF-a are crit-
ical for halting production of macrophage-derived chemokines
(Hodge-Dufour et al., 1998), and effector and memory CD4+
T cells can suppress macrophages’ production of IL-1b (Guarda
et al., 2009). Thus, even though a Th1 response can contribute to
inflammation, a subnormal Th1 response can prolong it.
Soluble Factors Contributing to Resolution
Above, we discussed the shifting nature and impact of cell
populations as inflammation resolves. Also driving resolution is
the secretion or extracellular formation of soluble products.
Resolution may fail if expression of these factors is delayed or
reduced. The examples discussed here illustrate their diversity:
cytokines, a protease inhibitor, gaseous signals, oxygenated
and nitrated lipids, a purine, and a neurotransmitter (Figure 4).
Among inflammation-resolving cytokines, many roads of
research lead to IL-10 and TGF-b, two of the most important
mediators of resolution of inflammation. Production of IL-10
generally requires two signals (Mosser and Zhang, 2008). One
signal may be immune complexes, prostaglandins, adenosine,
or apoptotic cells, while the other may be a TLR ligand (Mosser
and Zhang, 2008). Thus, full-scale production of IL-10 normally
ensues only after inflammation is likely to have developed.
Cases of Crohn’s disease that are attributable to a mutant
NOD2 protein illustrate the clinical significance of inadequate
IL-10 production during inflammation. Truncated NOD2 blocks
the ability of p38 kinase to phosphorylate a ribonucleoproteinCell 140, 871–882, March 19, 2010 ª2010 Elsevier Inc. 875
Figure 4. Examples of Mediators of
Resolution that Are Secreted or Formed
Extracellularlyrequired for transcription of IL-10 (Noguchi et al., 2009). Deficient
expression of IL-10 likely contributes to the sustained inflamma-
tion. Another explanation for Crohn’s disease, to be discussed
subsequently, may help explain why the disease is usually local-
ized to the bowel.
IL-10 and TGF-b are downstream points of convergence for
several other interacting cytokines that play important roles in
inflammatory resolution. For example, resolution of chemically-
triggered colitis in mice required IL-13, which served to increase
production of IL-10 and TGF-b (Fichtner-Feigl et al., 2008).
Other secreted proteins besides cytokines play controlling
roles in the resolution of inflammation, raising the possibility
that their subnormal release may be involved when inflammation
is abnormally persistent. A striking example is secretory leuko-
cyte protease inhibitor (SLPI). SLPI is secreted late in the
response of macrophages to inflammatory stimuli such as LPS
(Jin et al., 1997). SLPI suppresses the ability of TNF-a to activate
neutrophils. SLPI also binds to the epithelial growth factor pro-
granulin and protects it from digestion by elastase, an enzyme
normally released by activated neutrophils in response to TNF-a.
When digested by elastase, progranulin gives rise to granulins,
polypeptides that trigger epithelial cells to release the neutro-
phil-attracting chemokine IL-8. When protected by SLPI, the
intact progranulin molecule instead promotes epithelial repair
without chemokine production (Zhu et al., 2002). The SLPI-pro-
granulin axis is critical for resolution of inflammation in wounded
skin and for prompt closure of the wound (Zhu et al., 2002;
He et al., 2003).
Small, covalently reactive molecules such as ROI and reactive
nitrogen intermediates (RNI) are important anti-inflammatory
factors, although they are better known for proinflammatory
effects. These diffusible molecules display atomic rather than
molecular specificity and thereby integrate a wide range of
signaling reactions (Nathan, 2003). Pro- and anti-inflammatory
actions of ROI will be discussed below in connection with exces-
sive and subnormal responses, respectively. Here, we comment
briefly on RNI arising from NO, the primary product of iNOS
(NOS2), NOS1, and NOS3. Proinflammatory actions of RNI
cause lethal pneumonitis in mice infected with influenza virus
(Karupiah et al., 1998). One key mechanism may be that iNOS
binds, nitrosylates, and activates cyclooxygenase-2 (COX2)876 Cell 140, 871–882, March 19, 2010 ª2010 Elsevier Inc.(Mustafa et al., 2009). Nonetheless,
anti-inflammatory actions of NO are
also prominent, such as antagonizing
the adhesion of cells to endothelium,
inhibiting caspases and thus the genera-
tion of IL-1b and IL-18, and suppressing
the clonal expansion of T cells (Bogdan,
2001). A new anti-inflammatory action
of RNI involves signaling by nitro-fatty
acids, described below (Freeman et al.,
2008).The IL-10- and stress-induced enzyme heme oxygenase-1
produces bilirubin (an antioxidant) and carbon monoxide (CO).
CO not only mediates some of the anti-inflammatory effects of
IL-10 (Lee and Chau, 2002), but also enhances IL-10 expression
and suppresses LPS-induced production of TNF-a (Otterbein
et al., 2000). Another gaseous mediator, hydrogen sulfide
(H2S), can increase the production of CO. H2S is generated
from cysteine by cystathionine-g-lyase and cystathionine-b-syn-
thase (Szabo´, 2007). H2S can exert anti-inflammatory effects
in animals (Szabo´, 2007), but evaluation of its physiologic role
in inflammation awaits studies with the recently produced
knockout mice for the H2S-producing enzymes (Mustafa et al.,
2009) and better understanding of how its production is
regulated.
Diverse classes of oxygenated and nitrated lipids contribute to
the resolution of inflammation. In experimental inflammatory
exudates, the early oxygenation of arachidonic acid (20:4) into
inflammatory prostaglandins and leukotrienes is superseded
by conversion of arachidonate or 15-hydroxyeicosatetraenoic
acid into lipoxins. Lipoxins can suppress neutrophil chemotaxis,
vascular dilatation, vascular permeability, fibrosis, and pain,
while promoting emigration of monocytes and their ingestion of
apoptotic neutrophils (Serhan, 2007). Also generated in the
resolving phase are eicosapentaenoic acid (20:5)-derived resol-
vins and docosahexaenoic acid (22:6)-derived protectins
(Serhan, 2007) and maresins, the latter dependent on a 14-lipox-
ygenase (Serhan et al., 2009). The shifting profile of oxygenated
lipids reflects both the temporal expression of different enzymes
and the mobilization of different fatty acid substrates for use by
some of the same enzymes. Early events entrain later ones; for
example, prostaglandin E2 and prostaglandin D2 induce neutro-
phils to express 15-lipoxygenase, launching the production of
lipoxins (Serhan, 2007).
Arachidonic acid-derived epoxyeicosatrienoic acids (EETs)
produced by cytochrome P450 epoxygenases represent yet
another class of anti-inflammatory lipids. EETs can inhibit
NF-kB and block induction of COX2 and 50-lipoxygenase
(Node et al., 1999).
COX2 has also been found to switch from producing the
predominantly proinflammatory PGE2 early in inflammation to
producing cyclopentanone prostaglandins later on, such as
15-deoxy-D12,14-prostaglandin J. The latter blocks endothelium
from expressing VCAM-1, macrophages from releasing chemo-
kines, and adherent neutrophils from producing ROI, among
other anti-inflammatory actions (Lawrence et al., 2002). Thus,
while administration of COX2 inhibitors early is anti-inflamma-
tory, their late administration can prolong inflammation (Gilroy
et al., 1999), and there is a similar concern with 50-lipoxygenase
inhibitors (Serhan, 2007). This may help explain the failure of
COX2 inhibitors to limit brain damage in stroke patients.
Nitrated fatty acids are abundant in body fluids. They have
a potent ability to inhibit NF-kB, neutrophil activation, and
expression of iNOS and VCAM-1; to activate peroxisome
proliferator-activated receptor-g (PPARg); and to induce heme
oxygenase-1 (Freeman et al., 2008). Full appreciation of the
role of nitro-fatty acids awaits better understanding of how their
levels are regulated during adaptive andmaladaptive responses.
Lysophospholipids may also play an anti-inflammatory role.
For example, sphingosine-1-phosphate (S1P) bound to high-
density lipoproteins helps stimulate endothelial cells to release
NO (Nofer et al., 2004). NO arising in endothelium helps prevent
adherence of platelets and neutrophils. Endothelial cell S1P
receptor 3 (S1P3) may be particularly important in mediating
the tonic antipermeability effect of S1P in plasma. The diverse
actions of the five known S1P receptors on different cell types,
limited knowledge of S1P gradients in inflammatory states, and
the ability of some chemical probes considered antagonists to
behave as partial agonists contribute to the difficulty in evalu-
ating the anti-inflammatory role of S1P.
Additional autacoids are critical in restraining inflammation
and may be important in its resolution. For example, necrotic
cells release ATP, which is rapidly broken down by ectonucleo-
tidases, producing adenosine. Proinflammatory actions of
adenosine were noted above. However, the A2a adenosine
receptor is critical to suppress inflammation (Ohta and Sitkov-
sky, 2001), and its agonists can promote wound healing (Hasko´
and Cronstein, 2004).
Tracey and colleagues have illumined the existence of a
powerful anti-inflammatory pathway mediated by the vagus
nerve via its innervation of the viscera, particularly the spleen
and liver. Vagus nerve terminals release acetylcholine, which
acts on a7 nicotinic cholinergic receptors to suppress release
of TNF-a, IL-1b, IL-6, IL-8, andHMGB1bymacrophages in those
organs. Because this pathway is activated in the brain in
response to infection, injury, ischemia, and inflammatory cyto-
kines, it constitutes an ‘‘inflammatory reflex’’ (Tracey, 2007).
Electrical stimulation of the vagus or administration of cholin-
ergic agonists can exert a therapeutic effect in inflammatory
states (Tracey, 2007).
In sum, late in an inflammatory reaction, potent molecules that
signal via specific receptors to block inflammatory responses are
synthesized or released. This demonstrates that resolution of
inflammation is an active process, not merely what happens
when proinflammatory stimuli cease (Serhan, 2007).
Persistent Stimulation
The most straightforward cause of nonresolving inflammation is
the persistence of inflammatory stimuli of exogenous origin.
Persistent infections byM. tuberculosis, H. pylori, schistosomes,
and hepatitis viruses have been mentioned. Nondegradableparticles of asbestos and silica that trigger the inflammasome
(Dostert et al., 2008) promote chronic inflammation. However,
there are diverse types of persistent stimuli that are neither
infectious nor particulate. Some of these arise from what we
breathe or eat.
Exogenous lipid-binding proteins that are persistently present
in some environments, such as Derp2 from the feces of the dust
mite, can augment the host’s response to microbes, promoting
allergic responses. They do so by mimicking the function of
MD2, the LPS-binding chain of the TLR4 receptor complex
(Trompette et al., 2009). The allergic response is a form of inflam-
mation that can become chronic, even leading to fibrotic
changes (Galli et al., 2008).
Another form of persistent stimulation of inflammation arises
from the biosynthetic incorporation of a foreign food antigen
into self-molecules, with which antibodies then react. For
example, humans have a loss-of-function mutation in a gene
encoding an enzyme required for production of N-glycolylneura-
minic acid (Neu5Gc), which the human immune system can
therefore recognize as foreign (Hedlund et al., 2008). Dietary
Neu5Gc is taken up from red meat and dairy products, incorpo-
rated into cell surface glycans, and bound by antibody. The
resulting inflammation appears to promote angiogenesis and
oncogenesis in a COX2-dependent manner (Hedlund et al.,
2008).
Some chronic inflammatory diseases appear to begin with
repeated exposure to a toxin, leading to tissue injury that pro-
vokes an autoimmune reaction. The autoimmune reaction may
then perpetuate the inflammation. This is an emerging view of
chronic obstructive pulmonary disease, the fourth leading cause
of death in many industrialized countries. Cigarette smoke is a
major precipitant. In mice, the ability of cigarette smoke to
inflame the lungs requires TLR4 and MyD88. This suggests
a reaction to products of dead host cells or damaged extracel-
lular matrix. Cigarette smoke also impairs the ability of macro-
phages to ingest apoptotic cells. Large numbers of activated,
oligoclonal CD4+, and CD8+ T cells accumulate in the lungs,
along with B cell-rich lymphoid follicles (Cosio et al., 2009). Simi-
larly, recent evidence raises the possibility that obesity may be
propagated in part by an autoimmune reaction to an antigen
arising in adipose tissue. Th1 cells promoted obesity-associated
insulin resistance and weight gain in mice. T cells in visceral
adipose tissue had a biased antigen receptor repertoire, sug-
gesting that they had undergone local antigen-driven expansion
(Lo, 2009). The Th1 cells may activate macrophages in adipose
tissue, as discussed in the next section.
Cancers that thrive on the angiogenic products of inflamma-
tory cells are another cause of persistent proinflammatory
stimulation. Tumors court inflammatory cells by generating
chemokines (Mantovani et al., 2008) and can activate them by
producing matrix proteins like versican that bind to the TLR2-
TLR6 heterodimer (Kim et al., 2009).
Nonresolving Inflammation Linked to a Prolonged
or Excessive Response
Any molecular driver of inflammation can probably delay resolu-
tion of inflammation if its production goes on too long or at too
high a level. Here, we will illustrate this for one driver, ROI. ROI
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biologic processes because their effects are so widespread that
they can be misconstrued as nonspecific (Nathan, 2003). First,
we list examples of specific proinflammatory effects of ROI
that are new and striking. Then we illustrate contributions of
ROI to several major disorders in which non-resolving inflamma-
tion plays an important role.
A novel imaging method in the zebrafish has revealed that a
NOX-derived gradient of H2O2 develops within the first 3 min
after wounding and attracts leukocytes to the injury (Niethammer
et al., 2009). It seems likely that this H2O2-based chemoattrac-
tant mechanism operates in mammals as well. Also very early
after injury, ROI may activate the transient receptor potential
ion channel TRPA1 in chemosensory nerves, with proinflamma-
tory consequences (Caceres et al., 2009). When phagocytes
arrive, their NOX2 (phagocyte oxidase or phox) can activate
the inflammasome to drive production of IL-1b (Dostert et al.,
2008). Later on, in an inflammatory disease like influenza in
mice, NOX2 can contribute to the death of the host (Imai et al.,
2008), apparently by synergizing with RNI (Karupiah et al.,
1998) to produce peroxynitrite (Akaike et al., 1996).
Excess production of ROI plays a prominent role in the patho-
genesis of most if not of all the major diseases of nonresolving
inflammation. Mechanisms that get the lion’s share of attention
differ in each case. For example, in atherosclerosis (Galkina
and Ley, 2009), excess superoxide diverts endothelial-derived
NO from its anti-inflammatory and antihypertensive role into
the formation of peroxynitrite. Peroxynitrite damages mitochron-
dria and promotes more superoxide formation. In chronic
obstructive pulmonary disease (Cosio et al., 2009), oxidative
inactivation of a1-anti-trypsin, a2-macroglobulin, and SLPI
contributes to breakdown of elastic tissue.
Obesity is the form of nonresolving inflammation whose
incidence is rising the fastest. Thus, obesity serves here as a
focus for illustrating the role of excess ROI in a bit more detail.
For primary references, please see Nathan (2008). Excessive
caloric intake is associated with excessive production of ROI in
adipocytes, vascular smooth muscle, and endothelial cells.
The ROI arise from three intracellular sources—the mitochon-
drial electron transport chain, the endoplasmic reticulum, and
NOXs. In hypertrophied adipocytes, the large lipid vacuole
stores more oxygen than an equivalent volume of cytosol. The
engorged adipocytes compress blood vessels in the fat, making
themselves hypoxic. Hypoxia promotes mitochondrial dysfunc-
tion and leakage of electrons into ROI generation, which the
lipidic oxygen reservoir may sustain. The tiny cytosolic compart-
ment of the hypertrophied adipocyte contains a subnormal
quantity of antioxidant systems, and, on a per-molecule basis,
they are subnormally active. Thus, the hypertrophied adipocyte
may have a markedly adverse balance between oxidant produc-
tion and antioxidant defense. Excess ROI further disrupt
mitochondrial electron transport and promote their own forma-
tion. ROI can drive the production of a 4-OH-trans-2-nonenal,
a lipid aldhehyde that activates the proinflammatory ion channel
TRPA1. The lipid aldehyde also reacts with glutathione. Aldose
reductase acts on the adduct, generating glutathionyl-1,4-dihy-
droxynonane, which can induce TNF-a, IL-1b, IL-6, and
chemokines in macrophages (Yadav et al., 2009). Macrophages
accumulate, adipocytes necrose, and more macrophages878 Cell 140, 871–882, March 19, 2010 ª2010 Elsevier Inc.accumulate. Inflammatory cytokines arising in visceral adipose
tissue (see Review by G.S. Hotamisligil on page 900 of this issue)
circulate and adversely affect other tissues, including the vascu-
lature and the brain, where appetite regulation is further disor-
dered (Nathan, 2008).
Nonresolving Inflammation Linked to a Subnormal
Response
Paradoxically, a subnormal inflammatory response can engen-
der a prolonged response. This was perhaps first illustrated by
the exaggerated and ultimately lethal inflammatory response of
TNF-a/ mice to injection of Propionobacterium acnes (then
called Corynebacterium parvum) (Hodge-Dufour et al., 1998).
Here, we consider three recent examples that illustrate three
additional mechanisms: Crohn’s disease, whose genetic basis
is unknown in most cases; chronic granulomatous disease
(CGD), caused by genetic deficiency in NOX2; and influenza A
virus infection inmicewith an engineered deficiency in the gener-
ation of IL1-b and IL-18.
Work over three decades by Anthony Segal and colleagues, as
recently extended (Smith et al., 2009), suggests that a funda-
mental defect in macrophages from Crohn’s disease patients
(with or without NOD2 mutations) consists in the misdirection
of certain cytokines from the secretory pathway to lysosomal
degradation (Smith et al., 2009). The failure of macrophages to
release neutrophil-attracting cytokines when challenged with
large numbers of E. coli may lead to inadequate neutrophil
recruitment at sites of bacterial penetration of the intestinal
mucosa, resulting in a stronger inflammatory stimulus at a deeper
site than would be found in healthy subjects. In this view, what
would normally have been no inflammation or acute, resolving,
subclinical inflammation becomes recurrent, chronic, and
pathologic.
In CGD, a defect in the respiratory burst of neutrophils, mono-
cytes, and macrophages predisposes to recurrent, persistent
infection, and granulomatous inflammation. However, in both
Crohn’s disease and CGD, the relationship between infection
and nonresolving inflammation is likely to be complex, since
the granulomas (nodular accumulations of phagocytes and
lymphocytes, with or without a fibrous rim) are often found to
be microbiologically sterile. This could result from infection by
microorganisms we do not know how to detect, as was the
case until recently for Granulibacter bethesdensis in some
patients with CGD. However, it is also clear that deficient ROI
production can initiate or contribute to chronic inflammation in
the absence of infection. In a mouse model of CGD, this was
demonstrated by a nonresolving inflammatory response to
nonviable microbial products (Morgenstern et al., 1997).
Mechanisms for the anti-inflammatory role of ROI are begin-
ning to be identified. ROI activate the transcription factor Nrf2.
Nrf2-dependent upregulation of enzymes that synthesize the
antioxidant tripeptide glutathione is essential for resolution of
inflammation and repair of damaged tissue (Reddy et al.,
2009). ROI oxidize cholesterol to a form that activates liver X
receptors (LXRs), whose heterodimerization with retinoid X
receptor (RXR) leads to inhibition of expression of COX2,
iNOS, and IL-6 (Joseph et al., 2003). NOX2-generated super-
oxide is a cofactor for indoleamine dioxygenase, whose product,
kynurenine, is essential for the mouse to restrain what is
otherwise excessive IL-17 production and inflammation (Romani
et al., 2008).
Finally, mice lacking NLRP3 or caspase 1 were deficient in
production of IL-1b and IL-18 in response to influenza A virus,
were slower to recruit neutrophils and monocytes to the lung,
and produced lower amounts of TNF-a and IL-6 than the wild-
type (Thomas et al., 2009). Even though these mice controlled
the virus as readily as did wild-type mice, they paradoxically
sufferedmore epithelial necrosis, fibrosis, andmortality (Thomas
et al., 2009).
Challenges for Biology
There is now an enormous literature on nonresolving inflamma-
tion. However, understanding of the principles has not reached
a level that permits accurate predictions. Here are some key
challenges.
We have argued that clinically evident inflammation usually
begins in response to signals of two types, one type reporting
injury and the other infection, or in response to extensive injury
alone, which sensors for host cell necrosis interpret as being
accompanied by infection. In contrast, when chronic, nonresolv-
ing infection lacks an identifiable, persistent, exogenous
stimulus, it is not clear what signals sustain it. How widespread
is the role of the oxidized self-lipid that activates TLR4 (Imai
et al., 2008)? Does inflammation itself sometimes reset thresh-
olds so that receptors become sensitive to levels of proinflam-
matory signals that are normally ignored? Do chromatin modifi-
cations prolong responses to signals that have subsided?
We have stressed that cells like macrophages and T cells
and molecules like TNF and ROI can exert both pro- and anti-
inflammatory effects. We also emphasized the heterogeneity of
pathologic forms of chronic inflammation within an affected
organ. Does it follow that the same cells or signals can have
different effects in different microenvironments of the same
organ at the same time?
The impact of a signal depends on the other signals present as
well as their history (Nathan and Sporn, 1991). Thus, it is not
surprising that the same intervention may produce opposite
effects at different times or in different subjects. What informa-
tion do we need to predict the effect of blocking a given signal
in a given inflammatory disease at a given point in its progres-
sion? Does the state of the extracellular matrix offer a useful
record of a tissue’s history and a guide to its response (Nathan
and Sporn, 1991)?
Another theme has been the pervasive influence of ROI and
RNI in promoting and resolving inflammation. Perhaps the only
other class of signaling mediators with such a wide influence
on inflammation is the nuclear receptor superfamily. Many drugs
regulate nuclear receptors, but few effectively regulate ROI or
RNI. Can biology now guide the development of a clinically effec-
tive antioxidant pharmacology? Is it possible to develop selec-
tive inhibitors of specific sources of ROI and RNI, such as elec-
tron-leaking mitochondria, stressed endoplasmic reticulum,
uncoupled NOSs, and individual NOXs? Could some such inhib-
itors work by compensating for or reversing damage to mito-
chondria, endoplasmic reticulum, or NOSs?
We offered two illustrations of the concept that localized sites
may continue to drive a chronic inflammatory disorder that hasbecome systemic. Thus, we speculated that generation of
citrullinated proteins by peptidyl arginine deiminase from dying
neutrophils in rheumatoid joints may perpetuate the formation
of antigen-antibody complexes. We referred to evidence that
hypertrophic, macrophage-rich visceral fat generates cytokines
that affect not only the pancreas, vasculature, liver, and skeletal
muscle, but also the brain, dysregulating appetite control and
helping perpetuate obesity. Is there a biologic basis by which
to target potent anti-inflammatory therapies to localized sites,
minimizing the risks and toxicities of systemic action? For
example, can we exploit the differential expression of adhesion
receptors for this purpose or use inflammatory environments or
enzymes to activate prodrugs?
We have emphasized the molecular diversity of inflammation-
resolving signals. It is practical and customary to study them one
at a time. To our knowledge, there has been no study of a chronic
inflammatory state in which all known resolution factors—cyto-
kines, protease inhibitors, gaseous signals, oxygenated and
nitrated lipids, lysophospholipids, autacoids, neurotransmitters,
and so on—have beenmeasured at the same time and over time.
The potential value of a comprehensive evaluation seems clear,
even at the risk of spawning a term like ‘‘resolvome.’’
Implications for Therapy
The biologic complexity of nonresolving inflammation and our
limited understanding of it combine to make the development
of anti-inflammatory therapy particularly difficult. Moreover, the
most potent anti-inflammatory interventions have the potential
to increase the risk of infection, and every anti-inflammatory
therapy now in use has one or more potentially serious toxicities
of another kind.
Nonetheless, we should try to meet a challenge even more
demanding than suppressing nonresolving inflammation. The
goal should be to cure, not to palliate, inflammatory diseases.
For all the success of disease-modifying antirheumatic drugs
and biologics, for example, few patients with rheumatoid arthritis
achieve lasting remission after the cessation of therapy. In fact,
to our knowledge, no anti-inflammatory therapy cures the
majority of patients with a disease in which inflammation plays a
major contributory role, where ‘‘cure’’ means that the patient re-
turns to good health, or at least incurs no further tissue damage,
without ongoing treatment. Nor havemedical treatments that are
focused on pathogenic factors other than inflammation regularly
cured any of the major, noninfectious, inflammation-associated
diseases discussed in this review.
When dealing with major, chronic diseases of highmorbidity in
which inflammation plays a prominent part, we are likely to need
multi-pronged therapeutic approaches. An anti-inflammatory
component of therapy might synergize with components that
target other causal factors, particularly if it interrupts positive
feedback loops that help drive the disease (Nathan, 2008).
For an integrated therapeutic strategy to succeed, new kinds
of team approaches may be required, both in academia and in
industry. In academia, the biology of the cellular and soluble
factors that contribute to inflammation has traditionally been
the province of immunologists, pharmacologists, pathologists,
and hematologists. Biochemists, molecular biologists, microbi-
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studied metabolism; cell biologists, pathologists, and cardiolo-
gists have studied atherosclerosis; and immunologists and
pulmonologists have studied asthma. Inflammation and metab-
olism are highly interconnected, and each of these diseases
has much to teach those who study the others.
In the pharmaceutical industry, managers used to hand off
drug development projects from one team of specialists to
another in linear fashion, for example, from cell biologists or
immunologists to structural biologists to medicinal chemists to
pharmacologists and toxicologists and then to clinicians. Many
companies now convene teams in which all these disciplines
are represented at once so that interactions are multilateral
and iterative. This is a major advance, but even then, anti-inflam-
matory drug discovery is often relegated to one team that works
separately from others devoted to atherosclerosis, obesity,
asthma, chronic obstructive pulmonary disease, neurologic
disease, or cancer. Each team seeks to develop compounds
or biologics that show individual promise to meet that team’s
goals. Therapeutic strategies that involve combined interven-
tions, in which each intervention (a chemical, a biologic, or a
behavior) is designed from the outset to complement the others,
are almost never considered. Development of integrated thera-
peutic strategies will require building other kinds of teams.
Integrated therapeutic strategies should embrace the concept
that each intervention targets at least one pathway, not just a
molecule. The history of anti-inflammatory therapy is largely
the story of occasional, empirical success in modifying what
turn out to be control points on suitable pathways. In fact, early
anti-inflammatory agents were deployed long before their
targets were known. The targets proved to be enzymes (as for
aspirin and similarly acting nonsteroidal anti-inflammatory
agents) or transcription-regulating factors (as for glucocorti-
coids), and in some cases remain uncertain (as for gold salts).
Statins are among the highest-impact anti-inflammatory agents,
and their target, hydroxymethylglutaryl CoA reductase, was not
anticipated to have anything to do with inflammation. More
recently, successful anti-inflammatory agents were introduced
whose targets were identified in advance, such as cytokines
(TNF-a or IL-1b), receptors (for cysteinyl leukotrienes), or adhe-
sion molecules (a4 integrin). However, anti-inflammatories that
are clinically useful and acceptably safe are a fraction of those
whose development was undertaken.
Can we identify suitable pathways and control points by
approaches more efficient than trial and error? Can we predict
which individuals are more likely to benefit from a given interven-
tion and which more likely to suffer adverse effects? These
questions pertain to the biology, but there is also a need to
reduce empiricism and increase efficiency in the ensuing medic-
inal chemistry. As each lead compound is developed, vast quan-
tities of information are generated but then hidden away rather
than used to advance collective understanding. Information
sharing coupled with innovative statistical approaches could
provide a breakthrough for both target identification and phar-
maceutical development.
For target identification, the ‘‘genetics of genomics’’ (Chen
et al., 2008; Emilsson et al., 2008) holds promise to reveal
disease networks in terms of their edges and nodes. For the
anti-inflammatory component of a therapeutic strategy, we880 Cell 140, 871–882, March 19, 2010 ª2010 Elsevier Inc.need to understand what nodes have such connections and
such a balance of nonredundancy and redundancy that their
complete or partial interruption (or in some cases, enhancement)
can afford anti-inflammatory efficacy with a predictable and
acceptable level of risk. Thinking in terms of pathways will
encourage us to explore not only new targets in classes that
have provided historical success, but also targets in new
classes, such as channels that gate ions, enzymes that modify
chromatin, and small RNAs that control large ones.SUPPLEMENTAL INFORMATION
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